RxDoctor Payments Data

Paolo Colombo, MD

Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1336226810

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 84.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $14,788 and has fallen 89.6% since, to $1,538 in 2025.

$44,397in general payments, 2019–2025

Across 280 payments — averaging $158.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$38K
  • Roche Diagnostics International Ltd$5K
  • Novartis$747
  • Janssen Scientific Affairs, LLC$439
  • Medtronic$288
  • Abiomed$136
  • plus $523 from 11 others

What the payments were for

  • Speaking & faculty fees$25,25057%
  • Travel & lodging$6,29314%
  • Food & beverage$12,85429%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,397 in reported general payments places this provider in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

See all advanced heart failure and transplant cardiology providers in New York

Medicare billing

Part B allowed, 2024
$92,722
Medicare patients
206
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$238,785
Everolimus17$38,881
EntrestoSacubitril/Valsartan13$21,059
Daptomycin29$16,609
Mycophenolate Mofetil17$6,453
Repatha SureclickEvolocumab12$6,305
Tacrolimus14$3,874
Atorvastatin Calcium36$351
Metoprolol Succinate14$186
Prenatal Vitamin Plus Low IronPnv,calcium 72/Iron/Folic Acid15$181
Amlodipine Besylate21$97
Losartan Potassium17$77
Rosuvastatin Calcium27$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$747$21,05913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

Other advanced heart failure and transplant cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →